Cabbacis Information

Cabbacis Inc (OTCQB: CABI) is a tobacco product manufacturer focused on commercializing groundbreaking, patented risk-reduction products containing about 95 percent less nicotine. The mission of Cabbacis is to reduce the harm caused by smoking with its proprietary very-low-nicotine iBLEND® cigarettes and vaporizer pods in development, which predominantly contain very-low-nicotine tobacco with added hemp. Cabbacis holds a strong IP position ahead of the proposed FDA requirement to lower nicotine levels by about 95% in all cigarettes across the United States. The Company’s worldwide patent portfolio covering its iBlend® products includes 36 issued patents and various pending patent applications across the United States, Europe, China, India, Japan, Indonesia, Russia, South Korea, Canada, Australia, New Zealand, Mexico, Brazil and other jurisdictions. Cabbacis holds 8 U.S. patents. The Company’s clinical trial on smokers exclusively using four types of very-low-nicotine tobacco cigarettes made by Cabbacis with different level of hemp (0%, 5%, 10% & 20%) resulted in participants across all four cigarette types reporting a significant reduction in craving for their usual brand of cigarettes. Separately, focus groups have demonstrated that including hemp flower into very-low-nicotine cigarettes dramatically improves product acceptability, including improved taste and sensory characteristics. Smokers preferred iBLEND™, as compared to very-low-nicotine content cigarettes without hemp, by an approximate 3-to-1 margin! Very-low-nicotine cigarettes without hemp have been evaluated in dozens of independent studies. Results demonstrate, as reviewed in Donny and White (2022), that subjects smoked fewer cigarettes per day, reduced their nicotine dependence and exposure, and doubled their quit attempts. To learn more, please visit cabbacis.com.